MMP-9-IN-1
目录号 : GC38929
MMP-9-IN-1是基质金属蛋白酶-9(MMP-9)的特异性抑制剂。它通过选择性靶向MMP-9的血浆铜蓝蛋白(PEX)结构域发挥作用,Kd值为2.1μM。
Cas No.:502887-71-0
Sample solution is provided at 25 µL, 10mM.
MMP-9-IN-1 is a selective inhibitor of matrix metalloproteinase-9 (MMP-9),it works by targeting the plasma ceruloplasmin (PEX) domain of MMP-9, with a Kd value of 2.1μM[1]. MMPs consist of a pro-peptide sequence, a catalytic (CAT) metalloproteinase domain, a hinge region or linker peptide, and a hemopexin (PEX) domain, among which the PEX domain is particularly important[2]. MMP-9 plays key roles in various physiological and pathological processes, including extracellular matrix remodeling, tissue repair, inflammatory responses, and tumor invasion and metastasis[3]. Therefore, MMP-9-IN-1 is often used in related research areas such as cancer, inflammatory diseases, and neurodegenerative diseases[4-6].
In vitro, treatment of HT-1080 and MDA-MB-435 cells with 10μM MMP-9-IN-1 for 9 days significantly inhibits cell proliferation, migration and invasion without affecting cell viability[1]. Treatment of BMSCs with 10μM MMP-9-IN-1 for 72h significantly inhibited MMP-9 activity but no significant effect on the proliferation[7].
In vivo, C57BL6/J mice were intraperitoneally injected with MMP-9-IN-1 three days after ovariectomy (2mg/kg twice a week, for 8 weeks), MMP-9-IN-1 increased osteogenic differentiation protein expression, histone acetylation, promoted citric acid and acetyl-CoA secretion in BMSCs and restored osteogenic matrix formation in osteoblasts[7].
References:
[1] Dufour, A., Sampson, N. S., Li, J., Kuscu, C., Rizzo, R. C., Deleon, J. L., Zhi, J., Jaber, N., Liu, E., Zucker, S., & Cao, J. (2011). Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer research, 71(14), 4977–4988.
[2] Okusha, Y., Eguchi, T., Sogawa, C., Okui, T., Nakano, K., Okamoto, K., & Kozaki, K. I. (2018). The intranuclear PEX domain of MMP involves proliferation, migration, and metastasis of aggressive adenocarcinoma cells. Journal of cellular biochemistry, 119(9), 7363–7376.
[3] Farina, A. R., & Mackay, A. R. (2014). Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. Cancers, 6(1), 240–296.
[4] Das, S., Amin, S. A., & Jha, T. (2021). Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies. European journal of medicinal chemistry, 223, 113623.
[5] Rashid, Z. A., & Bardaweel, S. K. (2023). Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment. International journal of molecular sciences, 24(15), 12133.
[6] Alford, V. M., Kamath, A., Ren, X., Kumar, K., Gan, Q., Awwa, M., Tong, M., Seeliger, M. A., Cao, J., Ojima, I., & Sampson, N. S. (2017). Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS chemical biology, 12(11), 2788–2803.
[7] Da, W., Jiang, W., & Tao, L. (2024). ROS/MMP-9 mediated CS degradation in BMSC inhibits citric acid metabolism participating in the dual regulation of bone remodelling. Cell death discovery, 10(1), 77.
MMP-9-IN-1是基质金属蛋白酶-9(MMP-9)的特异性抑制剂。它通过选择性靶向MMP-9的血浆铜蓝蛋白(PEX)结构域发挥作用,Kd值为2.1μM[1]。MMPs具有前肽序列、催化(CAT)金属蛋白酶结构域、铰链区或连接肽和血凝素(PEX)结构域,其中PEX结构域是非常重要的结构域之一[2]。MMP-9在多种生理和病理过程中发挥重要作用,如细胞外基质重塑、组织修复、炎症反应以及肿瘤的侵袭和转移等[3]。因此,MMP-9-IN-1常用于相关研究,如癌症、炎症性疾病、神经退行性疾病等[4-6]。
在体外,10μM MMP-9-IN-1处理HT-1080和MDA-MB-435细胞9天可显著抑制细胞增殖、迁移和侵袭,但不影响细胞活力[1]。10μM MMP-9-IN -1处理骨髓间充质干细胞72h,可显著抑制MMP-9活性,但对骨髓间充质干细胞增殖无显著影响[7]。
在体内实验中,C57BL6/J小鼠在卵巢切除术三天后腹腔注射MMP-9-IN-1(2mg/kg,每周两次,持续8周),结果显示MMP-9-IN-1增加了骨髓间充质干细胞(BMSCs)中成骨分化蛋白的表达、组蛋白乙酰化,促进了柠檬酸和乙酰辅酶A的分泌,并恢复了成骨细胞中成骨基质的形成[7]。
Cell experiment [1]: | |
Cell lines | human HT-1080, and MDA-MB-435 cancer cell lines |
Preparation Method | Human HT-1080, and MDA-MB-435 cancer cell lines were maintained in DMEM (Invitrogen) containing 10% fetal calf serum. Cells (5 × 103 ) were added to a 96-well plate in the presence or absence of MMP-9-IN-1(10μM) for 9 days. Cell proliferation, migration, invasion and cytotoxicity weredetermined using the CellTiter-Glo™ Luminescent Assay. |
Reaction Conditions | 10μM; 9 days |
Applications | MMP-9-IN-1 significantly inhibits cell proliferation, migration and invasion without affecting cell viability. |
Animal experiment [2]: | |
Animal models | SPF grade C57BL6/J mice |
Preparation Method | Ten week-old female SPF grade C57BL6/J mice were randomly divided into 4 groups (6 mice in each group): control group (CON), sham operation group (Sham), ovariectomy group (OVX) and ovariectomy+MMP-9 inhibitor group (OVX + MMP-9-IN-1. Mice in the sham-operated group underwent dorsal skin excision and periovarian fat excision, while mice in the OVX group underwent bilateral oophorectomy after anaesthesia with an animal anaesthesia machine (oxygen flow was 0.5L/min, isoflurane inhalation concentration was 1%-3%). The OVX + MMP-9-IN-1 group was intraperitoneally injected with MMP-9-IN-1 three days after ovariectomy (2mg/kg, twice a week, for 8 weeks), and the other mice were injected with the same dose of phosphate-buffered saline (PBS). After 8 weeks of feeding, the mice were sacrificed by cervical dislocation, and the limbs were collected. Metabolite determination was carried out using ultrahigh-performance liquid chromatography–tandem mass spectrometry. Cells were harvested for Western blot. |
Dosage form | 2mg/kg, twice a week, for 8 weeks; i.p. |
Applications | MMP-9-IN-1 increased osteogenic differentiation protein expression, histone acetylation, promoted citric acid and acetyl-CoA secretion in BMSCs and restored osteogenic matrix formation in osteoblasts. |
References: |
Cas No. | 502887-71-0 | SDF | |
Canonical SMILES | O=C(NC1=CC=C(OC(F)F)C=C1)CSC2=NC(CCC)=CC(N2)=O | ||
分子式 | C16H17F2N3O3S | 分子量 | 369.39 |
溶解度 | DMSO: 125 mg/mL (338.40 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.7072 mL | 13.5358 mL | 27.0717 mL |
5 mM | 0.5414 mL | 2.7072 mL | 5.4143 mL |
10 mM | 0.2707 mL | 1.3536 mL | 2.7072 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet